Hopes of a coronavirus vaccine mount as three key biotech players make progress

Key Points

  • Over the last 48 hours, three biotech companies, in particular, have been thrust into the spotlight for their promise: BioNTech, CureVac and Moderna.
  • All three of these firms specialize in messenger RNA (mRNA) therapeutics.
  • These mRNA molecules are used to instruct the body to produce its own immune response to fight a range of different diseases.

The race is on to develop an immunization against COVID-19. 

Dozens of companies and public labs around the world are working to develop a vaccine to prevent the spread of the flu-like virus. Over the last 48 hours, three biotech companies, in particular, have been thrust into the spotlight for their promise: BioNTech, CureVac and Moderna.

All three of these firms specialize in messenger RNA (mRNA) therapeutics. These mRNA molecules are used to instruct the body to produce its own immune response to fight a range of different diseases. This type of vaccine can potentially be developed and produced more quickly than traditional vaccines.

Moderna is a Massachusetts-based biotech company working with the U.S. National Institutes of Health (NIH). It kicked off its first trial Monday in Seattle, Washington. 

This is called a “phase one” study and is being conducted by the NIH. Moderna is also preparing for a potential “phase two” study that it would conduct itself. Moderna shares rose 27% in Monday’s trading session.

BioNTech, meanwhile, is a German biotech company which recently announced two strategic partnerships to advance development of a vaccine. It formed a collaboration with Fosun Pharma to advance efforts in China, and with Pfizer to do the same outside China. 

Berenberg bank analysts say they are impressed with the company’s efforts to rapidly enter into an alliance with a top pharma company in China and they view it as an important validation of BioNTech’s mRNA technology platform. 

“BioNTech appears best positioned in the COVID-19 race owing to its diversified mRNA platform, delivery information and manufacturing capacity,” Berenberg said in a research note.

CureVac is an unlisted German company which aims to start testing an experimental vaccine on humans this summer. After reportedly getting caught in the political crossfire between Germany and the U.S., the European Commission pledged 80 billion euros of financial support to help them get a product out in Europe. 

On Monday, CureVac noted it “is working on expanding its manufacturing capacities to be able to provide up to billions of doses for outbreak situations like Covid-19.”

As evidenced by these companies, partnerships are key to developing and manufacturing vaccines for the public. Both public-private partnerships as well as partnerships between the traditional pharmaceutical giants and smaller biotech players can be critical to getting these vaccines from trial to market. 

However, the jury is still out on what type of therapeutic approach will work best. Barclays pharmaceutical research team noted that while mRNA vaccines remain unproven, they are likely to dominate the shorter-term headlines given faster development timelines and rapid early progress. 

Ultimately, the Barclays team believes these novel vaccines are likely to be superseded by more conventional approaches over time.

(Report by Julianna Tatelbaum)

This article was first published on CNBC https://www.cnbc.com/2020/03/17/hopes-of-a-coronavirus-vaccine-mount-as-three-key-biotech-players-make-progress.html and is republished with its permission.

Related Content

EU injects additional $17mn to tackle desert locusts ravaging East Africa

The European Union has released an additional 15 million euros to the fight against desert locusts in East Africa ahead of a potential new wave of swarms in the region. This comes after the EU granted 11 million euros back in February of this year for the same. The Food and Agriculture Organisation is one of the bodies set to receive the funds for this and CNBC Africa spoke to Cyril Ferrand, Senior Technical Officer and Team Leader for Eastern Africa Resilience for more.

Why Africa should embrace open banking

Digital transformation is a regarded as a key to drive up financial inclusion in Africa and open banking is one of the trends that are reshaping financial services. Polys Hadjikyriakos, Chief Business Development Officer at NETinfo Plc explains why the continent should embrace it.

How to identify potential growth sectors for SMEs amid COVID-19

Kenya-based SME consultancy firm, Viffa Consult, has begun identifying sectors with growth potential for SMEs and entrepreneurs to explore despite COVID-19 challenges. They’ve today released the first report in what will be a series, all about the coconut commodity market in Kenya. CNBC Africa spoke to Managing Director, Victor Otieno for more.

Uganda unveils new facility to help its SMEs recover from COVID-19

In Uganda like elsewhere, COVID-19 has made the situation for small businesses exceptionally challenging. Now in efforts to soften the blow, United Nations Development Programme has in partnership with Stanbic Bank Uganda launched a facility that aims to help small businesses recover from the impacts of the pandemic. Elsie Attafuah, UNDP Uganda Representative joins CNBC Africa for more.

Subscribe to our newsletter

Sign up for free newsletters and get more CNBC AFRICA delivered to your inbox

More from CNBC Africa

WHO warns of perpetual worsening of COVID-19 crisis

GENEVA/ZURICH (Reuters) - The new coronavirus pandemic raging around the globe will worsen if countries fail to adhere to strict healthcare precautions,...

Why Vestact is bullish on tech

Tech stocks have been hitting record highs in recent days, rallying by almost 16 per cent on the S&P 500 this year. Analysts have reported that the major tech companies will rally for as long as they can as investors are insulated from the worst of the Covid-19 market crisis. Byron Lotter, Portfolio Manager at Vestact joins CNBC Africa for more.

South Africa’s economy to shrink 6.9% in 2020 – S&P Global Ratings

JOHANNESBURG (Reuters) - South Africa’s economy will contract by more than initially projected, likely shrinking 6.9% in 2020 compared to an earlier...

Kenya, UK to resume talks on trade deal

British Prime Minister Boris Johnson and Kenya’s President Uhuru Kenyatta agreed to start negotiations for a post-Brexit trade agreement between the two nations. Economic Analyst, Reginald Kadzuzu joins CNBC Africa for more.

Partner Content

Tata International concludes a securitization transaction for its African Subsidiaries

UAE financial centers act as a gateway to benefit African businesses GCC, July 13th, 2020: Tata International Limited (TIL)...

Uber launches its largest region-wide initiative in partnership with Mastercard

Uber, in partnership with Mastercard to provide 120,000 free trips to frontline workers in MEA, including South Africa, Nigeria, Kenya, Ivory Coast...

Trending Now

Nigerian virus hunters in race against COVID-19 in Africa’s giant

LAGOS/ABUJA (Reuters) - Early one evening, Folasade Fadare and her team of four disease hunters piled into a van and headed for...

UK economy risks shrinking 14% this year, budget forecasters warn

LONDON (Reuters) - Britain’s economy could shrink by more than 14% this year and government borrowing risks approaching 400 billion pounds ($500...

South Africa to introduce universal income grant – minister

JOHANNESBURG (Reuters) - South Africa will introduce a universal basic income grant, the Minister of Social Development Lindiwe Zulu said on Monday,...

COVID-19 lock-down: Why the Black Business Council supports alcohol ban

The South Africa government has reinstated an alcohol ban and has made adjustments to travel restrictions under level 3 lock-down, in the hope of taking strain off from the healthcare sector and further reopening the economy. Joining CNBC Africa for more is the Black Business Council Treasurer General, Bonolo Ramokhele.
- Advertisement -